389th OMICS International Conference

OMICS International
conferenceseries.com

Scientific Program

5TH WORLD CONGRESS ON

CANCER THERAPY

SEPTEMBER 28-30, 2015
ATLANTA, USA

cancersummit.org

EXHIBITOR



OMICS International Conferences
2360 Corporate Circle., Suite 400 Henderson, NV 89074-7722, USA
Phone: +1-888-843-8169, Fax: +1-650-618-1417, Toll free: +1-800-216-6499
Toll free: +1-800-216-6499, Email: cancertherapy@conferenceseries.com

Scientific Program

Day 1 September 28, 2015

08:00-08:30 Registrations

Chattahoochee Salon C

OMICS International conferenceseries.com

08:30-08:55 **Opening Ceremony**

Keynote Forum

08:55-09:00 **Introduction**

09:00-09:25 **A review of cancer immunotherapies and nutritional therapies**

Jack C. Westman, University of Wisconsin School of Medicine & Public Health, USA

09:25-09:50 **BAI1 is a brain-specific tumor suppressor**

Erwin G. Van Meir, Winship Cancer Institute, Emory University, USA

09:50-10:15 **New simple method of detecting various cancers & their biochemical information from rapidly changing part of QRS complex of ECGs and its clinical application for screening and evaluation of cancer**

Yoshiaki Omura, New York Medical College, USA

10:15-10:40 **Systemic and interstitial photodynamic laser therapy: New options in oncology**

Michael Weber, Weber Medical, Germany

Coffee Break 10:40-10:55 @ Foyer

10:55-11:20 **Chemoprevention of experimental mammary carcinoma by *Trianthe ma portulacastrum* Linn., an Indian dietary and medicinal plant**

Anupam Bishayee, Larkin Health Sciences Institute College of Pharmacy, USA

Scientific Sessions:
Cancer Cell Biology, Diagnosis & Applied Research
Organ-Specific Cancer
Advances in Malignancy Counteractive Action and Screening

Session Chair: Yoshiaki Omura, New York Medical College, USA
Session Chair: Fereydoon Family, Emory University, USA

Session Introduction

11:20-11:40	**Non- Invasive, quick, simple diagnostic method and safe, effective, individualized treatment of various cancers without side effects**
	Yoshiaki Omura, New York Medical College, USA
11:40-12:00	**Identification of Quinones as growth inhibitors of Trastuzumab resistant breast cancer cells**
	Jayalakshmi Sridhar, Xavier University of Louisiana, USA
12:00-12:20	**Higher grade Gliomas have more diffused invasive fronts: Quantitative histology analysis of IDH1+ Gliomas**
	Fereydoon Family, Emory University, USA
12:20-12:40	**Exosomes in the treatment of pancreatic adenocarcinoma**
	Horacio Rilo, North Shore LIJ Health Systems, Hofstra University, USA
12:40-13:00	**Hepatocellular carcinoma screening in Cirrhosis: Inappropriate use of CT / MRI scan**
	Ashwani K. Singal, University of Alabama, USA

Group Photo	
Lunch Break 13:00-13:30 @ Restaurant	
13:30-13:50	**Atypical PKC signaling and breast cancer metastasis**
	Soumen Paul, University of Kansas Medical Center, USA
13:50-14:10	**Anti-Cancer preparation NSC 631570**
	Wassil Nowicky, Ukrainian Anti-Cancer Institute, Austria
14:10-14:30	**Target genes for acidosis-dependent anti-cancer drugs**
	Hiroshi Kobayashi, Chiba University, Japan
14:30-14:50	**Controlling Ras stability via the Wnt/β-catein signaling: Implication in cancer therapy**
	Kang-Yell Choi, Yonsei University, Korea
14:50-15:10	**Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKa and ERK1/2 signaling pathways in human non-small cell lung cancer cells**
	Swei Sunny Hann, University of Guangzhou Traditional Chinese Medicine, China
15:10-15:30	**RelB-mediated EMT activation promotesbone metastasis of prostate cancer**
	Yong Xu, Nanjing Medical University, China
15:30-15:50	**Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer**
	Taha A. Kumosani, King Abdulaziz University, Saudi Arabia
15:50-16:10	**UV light analisys of anticancer drug NSC 631570 in urine samples sorts healthy donors and prostate adenocarcinoma patients. Could the different drug up-take used to establish free-diagnosis cancer patients?**
	Larysa M. Skivka, ESC "Institute of Biology", Taras Shevchenko National University, Ukraine
Coffee Break 16:10-16:25 @ Foyer	
16:25-16:45	**The relevance of the cytological diagnostic in the mamary gland cancer**
	Ciobica Alin, Alexandru Ioan Cuza University, Romania
16:45-17:05	**Effect of dietary fatty acids on development of carcinogen-induced breast cancer in female fisher (F344) rats**
	Surekha MV, National Institute of Nutrition, India
17:05-17:25	**Sprague Dawley/NIN hairless mutant rat–A model to study carcinogenesis?**
	M. SatyaVani, National Institute of Nutrition, India
17:25-17:45	**Chemopreventive effects of ginger**
	Nirmala Kota, National Institute of Nutrition, India
17:45-18:05	***Sesame lignans*: Potent components as nutraceuticals/functional foods**
	Hemalatha Sanagaram, National Institute of Nutrition, India
18:05-18:25	**Clinical characterization of patients with diagnosis of lung cancer in Joaquin Albarran´s Teaching Hospital**
	Joan Fabian Fernandez de la Vega, General Calixto Garcia´s Teaching Hospital, Cuba
18:25-18:45	**The EGFR- targeted chimeric antigen receptor- modified T cells immunotherapy for patients with EGFR- expressing advanced or relapsed/refractory solid tumors**
	Weidong Han, The General Hospital of PLA, China
18:45-19:05	**Context specific role of deubiquitylase enzyme, USP9X in oral squamous cell carcinoma**
	Devathri Nanayakkara, Griffith University, Australia

Day 2 September 29, 2015	
Chattahoochee Salon C	
Scientific Sessions: **Anti Cancer Drugs & Delivery** **Novel Approaches to Cancer Therapeutics** **Cancer Therapy Clinical Cancer Research** **Cancer & Lifestyle Connection** **Complementary & Alternative Medicine (CAM)** **Cancer Biomarkers** **Cancer Nanotechnology**	
Session Chairs: **Yoshiaki Omura,** New York Medical College, USA **Sherri Z. Millis,** Advanced Individual Medicine, USA	
	Session Introduction
08:30-08:50	**Molecular engineering of Fc fusion proteins to tailor effector function to clinical indication**
	Steven Chamow, Chamow & Associates Inc., USA
08:50-09:10	**Cancer cell- state plasticity and resistance to therapy**
	Raffaella Sordella, Cold Spring Harbor Laboratory, USA
09:10-09:30	**Development of protein agent targeting Integrins αvβ3 at a novel site by rational protein design**
	Zhi-Ren Liu, Georgia State University, USA
09:30-09:50	**Hyaluronic Acid (HA) drug conjugates for targeted delivery of anticancer drugs: CA102N, A novel Hyaluronic acid conjugated drug against colorectal cancer**
	Eskouhie Tchaparian, Holy Stone Healthcare Co., Ltd., Taiwan
09:50-10:10	**Different uptake of Ukrain can explain the selective effect against pancreatic adenocarcinoma cell cultures *in vitro***
	Niccola Funel, University of Pisa, Italy
10:10-10:30	**A persulfide analog of the nitrosothiol SNAP, D-P*, induces apoptotic cell death in Jurkat leukemia T-cells**
	Burkhard Kloesch, Ludwig Boltzmann Institute for Rheumatology, Austria
	Coffee Break 10:30 - 10:45 @ Foyer
10:45-11:05	**Alkoxyamines for the *in-situ* generation of radicals as theranostic agents**
	Paul Bremond, Aix-Marseille University, France
11:05-11:25	**Tyrosine Isomers mediate the classical phenomenon of concomitant tumor resistance and exhibit a powerful anti-metastatic effect with undetectable toxic-side effects**
	Raul A. Ruggiero, National Academy of Medicine, IMEX-CONICET, Argentina
11:25-11:45	**Synthesis and preliminary mechanistic evaluation of N-(Substituted-1,3-Benzothiazol-2-yl)-2-(4-Substituted-Piperazin-1-yl) Acetamide derivatives with potent antiproliferative activity on human cancer cell lines**
	Mine Yarim, Yeditepe University, Turkey
11:45-12:05	**Anti-tumor activity of Wei-Shen: Pre- Clinical and clinical studies**
	Yuguo Yu, Jiangsu Andeson Biomedical Inc., China
12:05-12:25	**Gold nanorods-incorporated mesoporous magnetic nanoparticles for targeted drug delivery and near-infrared photothermal therapy in cancer**
	Hung-Wei Yang, National Sun Yat-sen University, Taiwan

12:25-12:45	**Assessment of the stemness-suppressive effects of several SHP-1 activators in human colorectal cancer cells**
	Yeu Su, National Yang-Ming University, Taiwan
12:45-13:05	**Modulated electro-hyperthermia: A local treatment may evoke distant anti-tumor response in a mice double colorectal allograft model**
	Tamas Vancsik, Semmelweis University, Hungary
	Lunch Break 13:05- 13:35 @ Restaurant
13:35-13:55	**Profiling cancer gene mutations in non-small cell lung cancer by droplet digital PCR**
	Dongqi Tang, The Second Hospital of Shandong University, China
13:55-14:15	**Assessment and treatment of cancer pain: Our experience in Serbia**
	Gvozdenovic Ljiljana, Clinical Center of Vojvodina, Serbia
14:15-14:35	**Nanotubes and their functions in cancer**
	H. Seda Vatansever, Celal Bayar University, Turkey
14:35-14:55	**Implications for antimicrobial, anticancer activity and molecular docking studies of N4-Tetradentate Tin macrocycles**
	Ekta Rawat, Kurukshetra University, India
14:55-15:15	**Development and preclinical testing of protein-based curcumin delivery forms for control of cancer**
	Lissy Krishnan, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India
15:15-15:35	**Bioengineered Fusokine GIFT4 for cancer immunotherapy**
	Jiusheng Deng, Emory University School of Medicine, USA
15:35-15:55	**Monoclonal antibodies that target pancreatic and colorectal cancer for both diagnosis and therapy**
	Myron Arlen, North Shore University Hospital, USA
	Coffee Break 15:55 - 16:10 @ Foyer
16:10-16:30	**^{13}C and ^{1}H NMR metabolic markers of therapeutic response upon signal transduction inhibitors in lymphoma cells and *in vivo***
	Seung-Cheol Lee, University of Pennsylvania, USA
16:30-16:50	**Next generation sequencing methodologies in identifying biomarkers and treatment options across cancers**
	Sherri Z. Millis, Advanced Individual Medicine, USA
16:50-17:10	**The effects of animal- assisted interventions (AAIs) for pediatric oncology patients and their parents at five hospital sites**
	Amy McCullough, American Humane Association, USA
17:10-17:30	**Alterations in actin binding proteins and miR~17-92 cluster in cancer cell metastasis and attenuation by DHA**
	Mehboob Ali, The Research Institute at Nationwide Children's Hospital, USA
17:30-17:50	**Cytoreductive surgery and HIPEC for peritoneal carcinomatosis of a gallbladder carcinoma**
	Elke Wagler, Department of General, Visceral and Oncosurgery, Pleißental-Klink Werdau, Germany
17:50-18:10	**Supporting the survivors: Cancer fatigue syndome and cancer rehabilitation**
	Naomi Dolgoy, University of Alberta, Canada
18:10-18:30	**Combining ultrasound and nanoparticle for cancer treatment**
	Chung-Hsuan (Winston) Chen, Genomics Research Center, Academia Sinica, Taiwan
Day 3 September 30, 2015	

Chattahoochee Salon C	
Scientific Sessions: **Cancer Chemotherapy** **Pediatric Oncology** **Anti-Cancer Agents in Medicinal Chemistry**	
Session Chairs: **Michael Weber,** Weber Medical, Germany **Deniz Peker,** University of Alabama, USA	
	Session Introduction
08:30-08:50	**A unique case of synchronous extramedullary spinal masses-is surgery an answer?**
	Rachana Yendala, University of Toledo Medical Centre, USA
08:50-09:10	**Feasibility assessment foroncology trials**
	Maxim Belotserkovskiy, Global Head Medical Affairs at PSI CRO AG, Switzerland
09:10-09:30	**Identifying the border of cutaneous squamous cell carcinoma by targeted EGFR antibodies conjugated to gold nanoparticles**
	Asaf Olshinka, Rabin Medical Center, Israel
09:30-09:50	**The presence of aflatoxin B1-FAPY adduct and Human Papilloma Virus in cervical smears from cancer patients in Mexico**
	Magda Carvajal, National Autonomous University of Mexico, Ciudad Universitaria, Mexico
09:50-10:10	**Cytotoxyc effect of *Solanum rastratum dunal* (mexican thisle) on cervical cancer cells (Siha)**
	Maria Del Carmen Valadez Vega, Instituto de Ciencias de la Salud, Mexico
10:10-10:30	**Polymorphisms in one- carbon metabolism pathway affect survival of Chinese resected gastric cancer patients**
	Jinfei Chen, Nanjing First Hospital, China
	Coffee Break 10:30 - 10:45 @ Foyer
10:45-11:05	**Analysis of APOBEC3 and driver genes polymorphisms in Moroccan patients with breast cancer**
	Chaymaa Marouf, University Hassan II Ain Chock, Morocco
11:05-11:25	**Estimating the total cost of cancer management: A descriptive prospective Cohort study among patients with cervical cancer at Ocean Road Cancer Institute, Dar es Salaam, Tanzania**
	Harrison R. Chuwa, Ocean Road Cancer Institute (ORCI), Tanzania
11:25-11:45	**First inhibitors of the human mitotic Kinesin MKLP-2 synthesis, biological evaluation and structure-activity relationships**
	Catherine Guillou, Gif Research Center, CNRS, LabEx, France
11:45-12:05	**Recognizing paediatric brain tumours in the emergency department**
	Babakhanlou R, University of Edinburgh, Scotland
12:05-12:25	**Design, synthesis and antiproliferative activity of 6-substituted Pyridazin- 3(2H)-ones**
	Mohamed Elagawany, Damanhour University, Egypt
12:25-12:45	**Cancer therapy, a review on anti neoplastic agent**
	Juhi Tiwari, Jayoti Vidyapeeth Women's University, India
12:45-13:05	**Secondary malignancies as long term adverse effects of chemo- and radiation therapy**
	Deniz Peker, University of Alabama, USA
	Lunch Break 13:05 - 13:35 @ Restaurant
Workshop on	
13:35-14:35	**The practical applications of lasers for photodynamic cancer therapy**
	Michael Weber, Weber Medical, Germany
14:35-14:55	**The Frequency of nucleophosmin1 gene mutation in newly diagnosed patients of acute myeloid leukaemia**
	Muhammad Ayyub, Armed Forces Institute of Pathology, Pakistan

14:55-15:15	**Association between GSTP1 genotypes and hormone receptors phenotype in invasive ductal carcinomas of breast**
	Marwan A. Bakarman, King Abdulaziz University, Saudi Arabia
15:15-15:35	**Resveratrol gold nanoparticles: Synthesis, characterization and *in-vitro* anticancer activity**
	Shrinivas Bumrela, Sinhgad Institute of Pharmaceutical Sciences, India
15:35-15:55	**Toxicological evaluation of anticancer α- Eleostearic acid rich fat extracted from seeds of bitter melon (*Momordicacharantia*) using a mouse model**
	K.N.K. Ranasinghe, University of Peradeniya, Sri Lanka
15:55-16:15	**First-in-class GnRH analog for cancer therapy**
	Gregory Lee, University of British Columbia, Canada
	Coffee Break 16:15 - 16:30 @ Foyer
16:30-16:50	**Inhibition of multidrug resistance protein I (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme**
	Tivnan A., Royal College of Surgeons in Ireland, Ireland
16:50-17:10	**SUMOylation: A link to future therapeutics**
	Faheem Ahmed Khan, Huazhong Agricultural University, China
17:10-17:30	**S.I.M.P.L.E.™ permanent hair removal as an option for unwanted hair growth experienced as a side-effect of cancer treatment drugs**
	Suzanne Anderer, Illinois School of Electrology, USA
17:30-17:50	**Fertility of female lymphoma patients treated with chemotherapy**
	Helen Gharwan, Sinai Hospital of Baltimore, USA
17:50-18:10	**TRB2-SKP2 signaling and SKP2 targeted therapy in human retinoblastoma and related tumors**
	Xiaoliang X. Xu, Zhongshan University, China
18:10-18:30	**Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors**
	Xia Xi, Peking University Shenzhen Hospital, China
	Award Ceremony
	Poster Session 16:00 - 17:00
CTPO01	**Prevalence of cell-free DNA mutations in patients with renal cell carcinoma: Preliminary findings**
	Christopher Keith, Emory University School of Medicine, USA
CTPO02	**Bacterial MazF mediated apoptosis in colorectal adenocarcinoma HT29 cells**
	Maryam Saffarian, Clemson University, USA
CTPO03	**G-quadruplex formation in the kRAS mid promoter region and identification of stabilizing small molecules as promising transcriptional silencers**
	Rhianna K Morgan, University of Mississippi, USA
CTPO04	**Potentiating of human papilloma vaccine candidate using Naloxone/Alum mixture as adjuvant: Increase of the immunogenicity and polarization to Th-17**
	Mahsa Yasaghi, Islamic Azad University of Pharmaceutical Science, Iran
CTPO05	**Adherence to postmastectomy radiation therapyamong N2/N3 female breast cancer in Taiwan and its associated predicting factors: a national wide retrospective population-based study**
	Zhen-Ying Liu, Koo Foundation Sun Yat-Sen Cancer Center, Taiwan
CTPO06	**Synthesis of functional liposomes for targeted chemotherapy and photodynamic therapy in brain tumor**
	Chih-Wen Lin, National Tsing Hua University, Taiwan
CTPO07	**Mesoporous nanoparticles-incorporated temperature-sensitive hydrogel for controlled drug/gene delivery in brain tumor**
	Feng-Wei Lin, National Sun Yat-sen University, Taiwan
CTPO08	**Hypodermic drug delivery for androgen inhibition using dissolving microneedle patches in prostate cancer therapy**
	Jing-Fong Liao, National Sun Yat-sen University, Taiwan

CTPO09	**Immunomodulatory molecules in glioblastoma multiforme tissues and primary cells**
	Shao-Chih Chiu, China Medical University, Taiwan
CTPO10	**Status of GSTP1 homozygous variant allele (Val/Val) genotype and susceptibility to colorectal cancer in Saudi Arabia**
	Marwan A. Bakarman, King Abdulaziz University, K. Saudi Arabia
CTPO11	**Pharmaco-dynamic of peptide HM-3 and its effect on HCT-116 tumor micro-environment Sitelbanat**
	Sitelbanat Yassin, China Pharmaceutical University, China

e-posters	
e-CTPO01	**What kinase gene expressed differently in primary and metastatic kidney cancer**
	Amy Zhao, University of Alabama, USA
e-CTPO02	**Morphofunctional inactivation of Jurkat T-cells by the titanium oxides coating**
	Khlusov I A, Siberian State Medical University, Russia
e-CTPO03	**Synthesis and apoptotic potential establishment of 1,2-oxaphospholes**
	Dobromir D Enchev, Konstantin PreslavskyUniversity, Bulgaria
e-CTPO04	**Molecular interaction studies of Anthraquinone derivatives, potent anticancer agents from the root of *Morinda Citrifolia* (Noni)**
	Shine. D., D. Y. Patil University, India
e-CTPO05	**The relevance of some molecular markers in recurrent pancreatic cancer: Focusing on CA 19-9 and cytokeratins**
	Alin Ciobica, Alexandru Ioan Cuza University, Romania
e-CTPO06	**The importance of clinical and instrumental diagnostic in the mamary gland cancer**
	Alin Ciobica, Alexandru Ioan Cuza University, Romania
e-CTPO07	**Studying the post-operatory and molecular modifications in the chronic pancreatitis and pancreatic cancer: Micronutrients and pancreatic enzyme supplementation**
	Alin Ciobica, Alexandru Ioan Cuza University, Romania
e-CTPO08	**A study regarding the quality of life evaluation in patients with terminal pancreatic cancer**
	Alin Ciobica, Alexandru Ioan Cuza University, Romania
e-CTPO09	**Psychological and psychiatric manifestations in patients with cancer**
	Alin Ciobica, Alexandru Ioan Cuza University, Romania
e-CTPO010	**Understanding tumoral markers in patients with pancreatic cancer**
	Alin Ciobica, Alexandru Ioan Cuza University, Romania
e-CTPO011	**Working with paradoxes: Moving from dialectical opposition to interdependent growth in culturally diverse female cancer survivors**
	Kirti Patel, Sofia University, USA

Closing Ceremony

Bookmark your dates

14th World Congress on

Cancer Therapy

December 08-10, 2016 Baltimore, USA

OMICS International
2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
contact@omicsgroup.com

OMICS International
5716 Corsa Ave., Suite 110, Westlake
Los Angeles, CA 91362-7354, USA
Ph: +1-650-268-9744
Fax: +1-650-618-1414
contact.americas@omicsonline.org

OMICS Group
SEZ Unit, Building No. 20, 9th Floor
APIIC Layout, HITEC City
Hyderabad-500081, Telangana, INDIA
Ph: 040-40131823, 040-47482222
contact.asiapacific@omicsonline.org

Toll free
USA & Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048